Gilead and Merck Gain FDA Approval for Sacituzumab Govitecan in Two First-Line TNBC Indications

A dual-indication approval granted on June 24, 2026 expands the manufacturing and supply footprint for two complex biologic modalities simultaneously: Gilead Sciences' antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) now carries first-line TNBC indications both as monotherapy and in combination with Merck's checkpoint inhibitor Keytruda (pembrolizumab), compressing timelines for contract manufacturers and QA teams already managing ADC fill-finish constraints.

The monotherapy indication, supported by the ASCENT-03 trial (NCT05382299, n=558), applies to adults with unresectable locally advanced or metastatic TNBC who are not candidates for PD-1 or PD-L1 inhibitor-based therapy. Median progression-free survival reached 9.7 months versus 6.9 months for investigator's choice chemotherapy (HR 0.62; 95% CI: 0.50, 0.77; p<0.0001), with a confirmed objective response rate of 50%.

The combination indication, supported by ASCENT-04/KEYNOTE-D19 (NCT05382286, n=443), targets PD-L1-expressing tumors (CPS ≥ 10) as determined by the PD-L1 IHC 22C3 pharmDx assay, an FDA-authorized companion diagnostic requirement that adds a pre-treatment testing step to patient selection workflows. Median PFS in the combination arm was 11.2 months versus 7.8 months for chemotherapy plus pembrolizumab (HR 0.65; 95% CI: 0.51, 0.84; p=0.0009), with confirmed ORR of 61%. Overall survival data remain immature across both trials.

For QA directors and plant heads, the operational read centers on the ADC manufacturing chain. Sacituzumab govitecan's cytotoxic payload classification requires containment controls consistent with 21 CFR Part 211 potent compound handling, and the combination regimen introduces a second biologic, pembrolizumab or the subcutaneous co-formulation Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), into the same treatment cycle. Contract manufacturers holding capacity for either product will need to assess scheduling, cleaning validation, and cross-contamination risk across shared fill-finish lines.

Prescribing information for sacituzumab govitecan-hziy carries a boxed warning for diarrhea and neutropenia, with additional warnings covering hypersensitivity, infusion-related reactions, nausea and vomiting, reduced UGT1A1 activity, and embryo-fetal toxicity. Pembrolizumab's label retains its established warnings for immune-mediated adverse reactions and infusion-related reactions. Regulatory affairs leads managing post-approval commitments should note that full prescribing information for Trodelvy, Keytruda, and Keytruda Qlex will be posted to Drugs@FDA.

With OS data still immature across both pivotal trials, label updates and potential post-marketing study requirements remain a live compliance consideration for both Gilead and Merck as follow-up data mature.

Source: FDA Drugs@FDA / What's New: Drugs RSS Feed, June 24, 2026.